Cost-Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non-Squamous NSCLC with High PD-L1 in Switzerland

被引：0
|
作者：
Pardo, E. [1 ]
Barbier, M. [2 ]
Panje, C. [3 ]
Gautschi, O. [4 ]
Lupatsch, J. [5 ]
机构：
[1] Canton Hosp Lucerne, Med Oncol, Internal Med, Luzern, Switzerland
[2] Univ Basel, Inst Pharmaceut Med Ecpm, Basel, Switzerland
[3] Cantonal Hosp St Gallen, Radiat Oncol, St Gallen, Switzerland
[4] Canton Hosp Lucerne, Luzern, Switzerland
[5] Univ Basel, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
cost-effectiveness; Pembrolizumab; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P08.03
引用
收藏
页码：S992 / S992
页数：1
相关论文
共 50 条
  • [41] Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis
    Rui, Mingjun
    Wang, Yingcheng
    Li, Yunfei
    Fei, Zhengyang
    BIODRUGS, 2024, 38 (01) : 157 - 170
  • [42] Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis
    Rui, Mingjun
    Wang, Yingcheng
    Li, Yunfei
    Fei, Zhengyang
    BIODRUGS, 2023,
  • [43] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF PD-L1 POSITIVE PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Nedzesky, J.
    Veenstra, D.
    VALUE IN HEALTH, 2022, 25 (07) : S343 - S343
  • [44] Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States
    Criss, Steven D.
    Weaver, Davis T.
    Sheehan, Deirdre F.
    Lee, Richard J.
    Pandharipande, Pari V.
    Kong, Chung Yin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (03) : 180.e11 - 180.e18
  • [45] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Li, Qiu
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 344 - 349
  • [46] Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
    Takumida, Hiroshi
    Horinouchi, Hidehito
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (03) : 737 - 746
  • [47] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND
    Harding, T.
    Insinga, R.
    Dawson, H.
    Bates, B. E.
    Arunachalam, A.
    Vandormael, K.
    VALUE IN HEALTH, 2019, 22 : S473 - S473
  • [48] Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.
    Takumida, Hiroshi
    Horinouchi, Hidehito
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA
    Alhammad, A.
    Lecca, Garrido S.
    VALUE IN HEALTH, 2016, 19 (07) : A741 - A741
  • [50] PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC
    Qin, Y.
    Jiang, L.
    Li, Y.
    Ren, L.
    Wang, Y.
    Gong, Y.
    Peng, F.
    Zhu, J.
    Ding, Z.
    Liu, Y.
    Yu, M.
    Lu, Y.
    Huang, M.
    ANNALS OF ONCOLOGY, 2019, 30
12345